Summary
According to the excitotoxicity hypothesis, neurotoxicity due to glutamate is regarded as potential factor in the progredient neurodegeneration of Huntington’s disease (HD). Memantine, as a glutamate receptor antagonist, should counteract this mechanism. Its effectiveness (up to 30 mg/day) with regard to retardation of progression was thus examined in 27 HD patients in a two year, open and multicentre trial. The results suggest that memantine treatment of HD may be useful in terms of retardation of the progression of the disorder.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Beal MF (1995) Ageing, energy and oxidative stress in neurode generative diseases. Ann Neurol 38: 357–366
Beal MF, Kowall NW, Ellison DW, Mazurek MF, Swartz KJ, Martin JB (1986) Replication of the neurochemical characteris tics of Huntington’s disease by quinolinic acid. Nature 321: 29–38
Bylsma FW, Rothlind J, Hall MR, Folstein SE, Brandt J (1993) Assessment of adapt ive functioning in Huntington’s disease. Mov Disord 8: 183–190
Ehle AL, Stewart RM, Lellied NA, Leventhal NA ( 1984) Evoked potentials in Huntington’s disease. Arch Neurol 41: 379–382
Erzigkeit H (1992) SKT: Ein Kurztest zur Erfassung von Gedächtnis-und Aufmerksamkeit sstorungen, Beltz Test Weinheim
Gerlach M, Riederer P, Youdim MBH (1996 ) Molecul ar mechanisms for neurodegeneration: synergism between reactive oxygen species, calcium and excitotoxic amino acids. Adv Neurol 169: 177–194
Guy W ( 1976) ECDEU. Assessment manual for psychopharmacology, revised edn. US Department of Health, Education and Welfare Washington DC
Huntington Study Group (1996) Unified Huntington’s disease rating scale. Reliability and consistency. Mov Disord 11: 136–142
Jellinger KA (2003) General aspects of neurodegeneration. J Neural Transm [Suppl] 65: 101–144
Kieburtz K, Koroshetz W, McDermott M, Beal MF, Greenamyre JT, Ross CA, Shoulson I, Cudkowicz ME, Sexton P, Skeuse C, Rosas D, Jenkins B, Rosenblatt A, Sherr M, Hersch S, Cell ar J, Guttman M, Brown C, Como PG, Marshall F, DeMarcaida JA, Zimmerman C, Marder K, Moskowitz C, Polanco C, Beltre J, Shannon K, Jaglin JA, Niederman F, Ashizawa T, Hunter C, Hauser R, Walker A, Gauger L, Hahn MA, Delgado H, Dawson T, Siemers E, Seeberger L, Dingmann C, Dubinsky R, Gray C, Weiner WJ, Rodriguez-Batemen D, Albin RL, Wernette K, Harrison M, Rost-Ruffner E, Paulsen J, Rodnitzky RL, Dobson J, Vining L, Suchowersky O, Pantella C, Saint-Hilaire MH, Furtado J, Martin W, Wieler M, Walker F, Hunt V, Raymond L, Almqvist E, Rubin A, Blair B, Marek K, Caplan K, Baker D, Brocht A, Casaceli C, Orme C, Rudolph A, Rumfola L, Schifitto G, Shinaman A, Sulimowicz K, Watts A, Eapen S, Zhang L, The Huntington Study Group (2001) A randomized, placebocontrolled trial of coenzyme Q(10) and remacemide in Huntington’s disease. Neurology 57: 397–404
Kremer B, Clark CM, Almqvist EW, Raymond LA, Graf P, Jacova C, Mezei M, Hardy MA, Snow B, Martin W, Hayden MR (1999) Influence of lamotrigine on progression of early Huntington disease — a randomized clinical trial. Neurology 53: 1000–1011
Lange HW (1983) Quantitative changes of telencephalon, diencephalon and mesencephalon in Huntington’s chorea, postencephalitic and idiopathic parkinsonism. Verh Anat Ges 75: 923–925
Lehrl S, Gallwitz A, Blaha L, Fischer B (1980) Kurztest für allgemein e Intelligenz KAI. VLESS Vaterstetten
MacDonald ME, Gusella JF (1996) Huntington’s disease: translating a CAG repeat into a pathogenic mechanism. Cuff Opin Neurobiol 6: 638–643
Murman DL, Giordani B, Mellow AM, Johanns JR, Little RJA, Hariharan M, Foster NL (1997) Cognitive, behavioral, and motor effects of the NMDA antagonist ketamine in Huntington’s disease. Neurology 49: 153–161
Parsons CG, Danysz W, Quack G (1999) Memantine is a clinically well tolerated NMDA receptor antagonist-a review of preclinical data. Neuropharmacology 138: 735–767
Pellegrini JW, Lipton SA (1993) Delayed administration of memantine prevents N-methyl-Daspartate receptor mediated neurotoxicity. Ann Neurol 33: 403–407
Raitan RM (1956) Trail Making Test. Manual for administration, scoring and interpolation. Indiana University Press Indianapolis
Shoulson I, Fahn S (1979) Huntington disease; clinical care and evaluation. Neurology 29: 1–3
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Springer-Verlag Wien
About this chapter
Cite this chapter
Beister, A., Kraus, P., Kuhn, W., Dose, M., Weindl, A., Gerlach, M. (2004). The N-methyl-D-aspartate antagonist memantine retards progression of Huntington’s disease. In: Müller, T., Riederer, P. (eds) Focus on Extrapyramidal Dysfunction. Journal of Neural Transmission. Supplementa, vol 68. Springer, Vienna. https://doi.org/10.1007/978-3-7091-0579-5_14
Download citation
DOI: https://doi.org/10.1007/978-3-7091-0579-5_14
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-21114-4
Online ISBN: 978-3-7091-0579-5
eBook Packages: Springer Book Archive